Asia Pacific
Refine Search
Biotechnology
Targeted alpha therapy (TAT), or radioligand therapy, is a recent hot area that attracted big pharmas like Bristol Myers Squibb and Novartis. 5 September 2024
Biosimilars
Biosimilar-focused biopharmaceutical company and contract development and manufacturing organization (CDMO) Tanvex BioPharma has named Stephen Lam its new chief executive (CEO). 5 September 2024
Biotechnology
Privately-held Chinese biotech EpimAb Biotherapeutics and Vignette Bio have entered into a license agreement for EpimAb’s BCMA-targeting T-cell engager (TCE) EMB-06. 5 September 2024
Biotechnology
Rigel Pharmaceutical’s shares dipped 4.4% to $12 .85 by late morning, despite announcing what could be a lucrative deal for the company. 3 September 2024
Biotechnology
Chinese gene therapy specialist YolTech Therapeutics has entered into an exclusive licensing agreement with Salubris Pharmaceuticals (SHE: 002294). 3 September 2024
Biotechnology
Japan’s Nxera Pharma today announced that it will receive a $35 million payment from Neurocrine Biosciences, triggered by the successful completion of the Phase II trial with NBI-1117568 (NBI-‘568) in adults with schizophrenia. 2 September 2024
Biotechnology
Chinese biopharma Hutchmed on Friday announced that it has voluntarily withdrawn its supplemental New Drug Application (NDA) in China for fruquintinib. 2 September 2024
Pharmaceutical
Jacobio Pharma announced that it has granted the China rights to KRAS G12C inhibitor glecirasib and SHP2 inhibitor JAB-3312 to Shanghai Allist Pharmaceuticals. 2 September 2024
Pharmaceutical
Mundipharma International has failed to find a buyer for its Chinese unit after its latest attempt at selling it, according to Reuters. 30 August 2024
Pharmaceutical
Japanese drugmaker Chugai Pharmaceutical says it will transfer the business of the secondary hyperparathyroidism drug Oxarol for Injection (maxacalcitol) to LTL Pharma in Japan. 29 August 2024
Biotechnology
Chinese biotech DualityBio has shown that it means business in a filing to the Hong Kong stock exchange that reveals its plans for an initial public offering (IPO). 28 August 2024
Pharmaceutical
Japanese pharma major Astellas Pharma today revealed that the European Commission has granted Marketing Authorization for Padcev (enfortumab vedotin, an antibody-drug conjugate [ADC]) in combination with Keytruda (pembrolizumab). 28 August 2024
Biotechnology
Chugai Pharmaceutical has announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved an additional indication for Alecensa (alectinib). 28 August 2024
Biotechnology
Cancer vaccines represent a burgeoning field in oncology and have been heralded as having the potential to revolutionize treatment. 27 August 2024
Biosimilars
South Korea’s Celltrion yesterday announced the European Commission (EC) approval for the use of SteQeyma (CT-P43), an ustekinumab biosimilar referencing Stelara, for the treatment of multiple chronic inflammatory diseases. 27 August 2024
Biotechnology
China's National Medical Products Administration (NMPA) has approved domestic biopharma firm Innovent Biologics’ Dupert (fulzerasib) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harboring KRAS G12C mutation who have received at least one systemic therapy. 22 August 2024
Pharmaceutical
Germany's pharmaceutical sector is on high alert for potential drug shortages, following China’s recent intensification of its espionage laws. 21 August 2024
Biotechnology
AstraZeneca (LSE: AZN) has announced that Fasenra (benralizumab) has picked up a new approval from China's National Medical Products Administration (NMPA). 20 August 2024
Biotechnology
The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has approved Padcev (enfortumab vedotin) for the treatment of adult patients with locally advanced or metastatic urothelial cancer. 20 August 2024
Pharmaceutical
Japanese drugmaker Ono Pharmaceutical (TYO: 4528) has announced that the US medicines regulator will consider vimseltinib under the Priority Review scheme. 16 August 2024
Biotechnology
The European Commission (EC) has approved tislelizumab as a treatment for non-small cell lung cancer (NSCLC) across three indications, including first- and second-line use. 26 April 2024
Biotechnology
Long-term partners BioArctic and Eisai have announced a new research agreement regarding BAN2802, a potential treatment combining the former company’s proprietary BrainTransporter technology with an undisclosed Alzheimer drug candidate. 23 April 2024
Pharmaceutical
Japanese drug majors Takeda Pharmaceutical and Astellas Pharma, along with Sumitomo Mitsui Banking, today announced the signing of a master agreement to establish a joint venture company. 22 April 2024
Biotechnology
Japanese drugmaker Chugai today announced that it concluded a license agreement with its majority owner, Swiss pharma giant Roche, for zilebesiran, 19 April 2024
Pharmaceutical
New data from Japanese drugmaker Shionogi’s largest European real-world evidence study of cefiderocol (PERSEUS), demonstrates strong efficacy in critically ill patients with difficult to treat carbapenem-resistant (CN) Gram-negative (GN) bacterial infections. 19 April 2024
Pharmaceutical
Taiwanese infectious disease specialist TaiGen Biotechnology has announced positive results from a Phase III trial of TG-1000. 19 April 2024
Biotechnology
US privately-held Kumquat Biosciences today announced a strategic and exclusive collaboration with Japan’s Takeda to develop and commercialize a novel immuno-oncology (I-O) small molecule inhibitor as a mono- and/or combination-therapy. 17 April 2024
Pharmaceutical
The Japanese Ministry of Health, Labor, and Welfare (MHLW) has approved Fintepla (fenfluramine) oral solution for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) as an add-on therapy to other anti-epileptic medicines for patients two years of age and older. 17 April 2024
Biotechnology
Japanese drugmaker Astellas expects to book an impairment charge of 70 billion yen ($453 million) in the fourth quarter of Japan’s 2023 fiscal year, which ended last month. 16 April 2024
Pharmaceutical
Japanese drugmaker Nxera Pharma has entered into an exclusive supply and distribution agreement with Handok to commercialize Pivlaz (clazosentan sodium) 150mg in South Korea. 15 April 2024
Biotechnology
Japanese conglomerate Fujifilm Holdings Corporation is to invest a further $1.2 billion to expand its large-scale cell culture CDMO business in North Carolina, USA. 12 April 2024
Biotechnology
Antibody drug conjugates (ADCs) are currently in vogue with investors and big pharma, as a rapidly emerging class of therapeutic agents that combine the target specificity of a monoclonal antibody with the lethality of cytotoxic cellular poison. 10 April 2024
Pharmaceutical
Japan-based Teijin Group’s healthcare business, Teijin Pharma, has entered into an exclusive global licensing agreement with French drugmaker Bioprojet Pharma. 10 April 2024
Pharmaceutical
Sino Biopharmaceutical revealed it has entered into a strategic partnership with Boehringer Ingelheim to bring the German family-owned company’s innovative cancer therapies to the market in mainland China. 9 April 2024
Pharmaceutical
An FXR agonist developed by Ascletis Pharma has not performed well in mid-stage trials, leading the Hangzhou, China-based firm to dial down its investment in the drug. 8 April 2024
Biotechnology
Two frequent words that people often hear in recent China’s pharma industry comments are “Chu Hai” and “Nei Juan”. The former means “selling overseas,” while the latter means “cut throat competition.” 8 April 2024
Biotechnology
The US Food and Drug Administration on Friday granted accelerated approval to Enhertu (fam-trastuzumab deruxtecan-nxki) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors. 6 April 2024
Pharmaceutical
In the next decade, Japan’s largest drugmaker Takeda Pharma is hoping to bring more Chinese developed drugs to the global market by working with local partners in some key therapeutic areas, said its leaders at Takeda R&D China innovation forum held in Shanghai. 5 April 2024
Biotechnology
Japanese pharma company Nippon Shinyaku and privately-held UK small activating RNA (RNAa) therapeutics specialist MiNA Therapeutics have announced a collaboration. 5 April 2024
Pharmaceutical
A new licensing deal has been agreed between American firm Incyte and Hong Kong-based China Medical System Holdings (CMS). 2 April 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze